Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q2 2018 (← Previous) (Next →)

Filing Date: Aug 14, 2018

Total Value ($000): $498,793 (100.0% shares, 0.0% debt)

Holdings (10)

BIIB BIOGEN INC. 26.9%

Value ($000) $134,049 Shares 461,858 Est. Cost $285.21 Unrealized -1.4%

— MEDICINES CO. 14.1%

Value ($000) $70,537 Shares 1,922,000 Est. Cost $29.43 Unrealized —

IRWD IRONWOOD PHARMACEUTICALS INC. 12.9%

Value ($000) $64,378 Shares 3,367,100 Est. Cost $12.76 Unrealized +16.0%

INVA INNOVIVA INC. 12.5%

Value ($000) $62,583 Shares 4,535,000 Est. Cost $11.88 Unrealized +26.1%

— ALLERGAN PLC 11.5%

Value ($000) $57,351 Shares 344,000 Est. Cost $164.77 Unrealized —

— INTERCEPT PHARMACEUTICALS INC. 10.7%

Value ($000) $53,308 Shares 635,300 Est. Cost $60.63 Unrealized —

— SHIRE PLC 10.5%

Value ($000) $52,159 Shares 309,000 Est. Cost $152.21 Unrealized —

— NOVELION THERAPEUTICS INC. 0.8%

Value ($000) $3,772 Shares 1,025,000 Est. Cost $8.42 Unrealized —

— APRICUS BIOSCIENCES INC. 0.1%

Value ($000) $564 Shares 1,447,906 Est. Cost $1.30 Unrealized —

ABBV ABBVIE INC. 0.0%

Value ($000) $92 Shares 1,000 Est. Cost $38.85 Unrealized +81.5%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
BIIB	BIOGEN INC.	461,858	$134,049	26.9%	$285.21	-1.4%	COM	09062X103
—	MEDICINES CO.	1,922,000	$70,537	14.1%	$29.43	—	COM	584688105
IRWD	IRONWOOD PHARMACEUTICALS INC.	3,367,100	$64,378	12.9%	$12.76	+16.0%	COM CL A	46333X108
INVA	INNOVIVA INC.	4,535,000	$62,583	12.5%	$11.88	+26.1%	COM	45781M101
—	ALLERGAN PLC	344,000	$57,351	11.5%	$164.77	—	SHS	G0177J108
—	INTERCEPT PHARMACEUTICALS INC.	635,300	$53,308	10.7%	$60.63	—	COM	45845P108
—	SHIRE PLC	309,000	$52,159	10.5%	$152.21	—	SPONSORED ADR	82481R106
—	NOVELION THERAPEUTICS INC.	1,025,000	$3,772	0.8%	$8.42	—	COM NEW	67001K202
—	APRICUS BIOSCIENCES INC.	1,447,906	$564	0.1%	$1.30	—	COM NEW	03832V307
ABBV	ABBVIE INC.	1,000	$92	0.0%	$38.85	+81.5%	COM	00287Y109